Lockdown measures during the COVID-19 pandemic strongly impacted the circulation of respiratory pathogens in Southern China

Heping Wang¹,², Yuejie Zheng¹, Marien I. de Jonge², Rongjun Wang¹, Lilly M. Verhagen²,³, Yunsheng Chen¹, Li Li¹, Zhi Xu⁴ & Wenjian Wang¹*

A range of public health measures have been implemented to suppress local transmission of coronavirus disease 2019 (COVID-19) in Shenzhen. We examined the effect of these measures on the prevalence of respiratory pathogens in children. Clinical and respiratory pathogen data were collected for routine care from hospitalized children with acute respiratory infections in Shenzhen Children’s Hospital from July 2018 to January 2022. Nasopharyngeal swabs were collected and respiratory pathogens were detected using standardized clinical diagnostics as part of routine care. Data were analyzed to describe the effects of COVID-19 prevention procedures on other common pathogens. A total of 56,325 children under 14 years of age were hospitalized with an acute respiratory infection during the study period, 33,909 were tested from July 2018 to January 2020 (pre-lockdown), 1168 from February 2020 to May 2020 (lockdown) and 21,248 from July 2020 to January 2022 (post-lockdown). We observed a 37.3% decline of routine care in respiratory infection associated hospital admission in the 19 months’ post-lockdown vs. the 19 months’ pre-lockdown. There were 99.4%, 16.0% and 1.26% reductions measured for Mycoplasma pneumoniae, influenza virus A and adenovirus, respectively. However, a 118.7% and 75.8% rise was found for respiratory syncytial virus (RSV) and human parainfluenza virus (HPIV) during the 19 months’ post-lockdown in comparison to the pre-pandemic period. The detection of RSV especially increased in toddlers after the lockdown. Lockdown measures during the COVID-19 pandemic led to a significant reduction of Mycoplasma pneumoniae, influenza virus A and adenovirus infection. In contrast, RSV and HPIV infection increased.

Abbreviations

InfA  Influenza A  
InfB  Influenza B  
HPIV  Human parainfluenza virus  
RSV  Respiratory syncytial virus  
AdV  Adenoviruses  
HMPV  Human metapneumovirus  
HRV  Human rhinovirus  
HBoV  Human bocavirus  
HCoV  Human coronavirus  
Ch  Chlamydia  
MP  Mycoplasma pneumoniae  
PCR  Polymerase chain reaction

¹Shenzhen Children’s Hospital, No. 7019 Yitian Road, Futian District, Shenzhen 518038, Guangdong, China. ²Department of Laboratory Medicine, Laboratory of Medical Immunology, Radboud University Medical Center, Nijmegen, The Netherlands. ³Department of Pediatric Infectious Diseases and Immunology, Amalia Children’s Hospital, Radboud University Medical Center, Nijmegen, The Netherlands. ⁴Ningbo Health Gene Technologies Co., Ltd, Ningbo, Zhejiang, China. *email: wwjxx@126.com
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was first detected in December 2019 in Wuhan. The World Health Organization (WHO) declared the outbreak to be a pandemic on March 11, 2020. Subsequent implementation of non-pharmaceutical interventions (e.g., cessation of global travel, mask use, regular hand-sanitizing and hand-washing, physical distancing, avoiding gatherings, and staying home) reduced transmission of SARS-CoV-2. It is observed that SARS-CoV-2 measures may also be effective in reducing acute respiratory infectious (ARIs) diseases, such as seasonal influenza, outpatient pneumonia.

Shenzhen is a large migratory city located in southern China, north of Hong Kong. Shenzhen, like most domestic cities in China, has implemented strict COVID-19 prevention and control measures from February 2022. For specific measures, including the wearing of masks, social distancing, and avoidance of gathering-related activities, refer to the paper published by our group. Public health measures, such as wearing masks, washing hands, and disinfecting hands with alcohol are effective against various infectious diseases, including rotavirus, norovirus and respiratory infections.

Influenza virus is one of the most concerned seasonal pathogens, a reduction in the number of people infected with the influenza virus in 2020 compared to the previous year was observed in studies from Japan, France, Singapore, Mexico, Hong Kong and Zhejiang province in China. We have also previously reported a significant reduction in the incidence of respiratory pathogens post-lockdown, however this measures in a different period, only from September to December (2020) and not year round as described in this study. Current infection control measures for COVID-19 impacted the respiratory infections focused on the effects of Center for Disease Control and Prevention (CDC) population-wide data, and only a few studies have focused on children over long periods of time. Here, we assessed the change of the seasonal influenza virus incidence and respiratory pathogen infections pre- and post-lockdown in hospitalized children for 42 months.

**Materials and methods**

**Patients information.** Patients with ARI between July 2018 and January 2022 admitted to the pediatric wards were enrolled in Shenzhen Children’s Hospital. The inclusion criteria were as follows: age below 14 years and one or more respiratory symptoms involving the respiratory tract (rhinorrhea, sore throat, cough, dyspnea/ tachypnea), SARS-CoV-2 were not detected since January 2020. The exclusion criteria were as follows: repeated the detection within one week, the patient was over 14 years old, and the age or gender information was incomplete. Laboratory and demographic data of the patients enrolled in this study were retrieved from the Shenzhen Children’s Hospital electronic patient dossiers. The study protocol was approved and waived informed consent by the Ethical Committee of Shenzhen Children’s Hospital (201601304). The study was performed in accordance with relevant guidelines and regulations.

**Statistical analyses.** We compared the overall number of hospitalized children before and after the lockdown measures, described by monthly distribution. Paired t-test was performed according to the monthly number of children to observe the differences of hospitalized children pre- and post-lockdown. At the same time, the age composition ratio of hospitalized children was observed in pre- and post-lockdown. We compared age-group hospitalization rates for respiratory pathogens for the 19 months’ post-lockdown measures at the end of January 2022 with rates from the pre-lockdown 19 months.

The overall detection rate and prevalence of common pathogens, including respiratory syncytial virus (RSV), adenovirus (AdV), influenza A/B (InfA/B) and parainfluenza virus (HPIV, types 1, 2 and 3) and M. pneumoniae (Mp), were compared pre-and post-lockdown periods. Differences in detection methods were also taken into account when comparing. At the same time, to observe the seasonal prevalence of the pathogens, including human metapneumovirus (HMPV), human rhinovirus (HRV), human bocavirus (HBoV), human coronavirus (HCoV, 229E, OC43, NL63 and HKU1), Chlamydia pneumoniae (Cp), expanded by the GeXP-based multiplex reverse transcription polymerase chain reaction (PCR) assay started in September 2019. We compared PICU admission and respiratory pathogens detection rates between the pre-lockdown and post-lockdown period and whether it was consistent with the overall prevalence.

SPSS 21.0 was used to analyze difference in patient number and pathogen prevalence with 95% confidence intervals. Descriptive statistics and paired t-test were applied to describe patient characteristics and difference. Categorical variables were analyzed by Pearson’s chi-square test. P < 0.05 was considered statistically significant.

**Results**

**Patient characteristics.** A total of 56,325 children with ARIs were enrolled in this study, 33,909 were tested from July 2018 to January 2020 (pre-lockdown), 1168 from February to May 2020 (lockdown) and 21,248 from July 2020 to January 2022 (post-lockdown), indicating a 37.3% reduction in hospital admissions due to ARI comparing the post-lockdown versus the pre-lockdown period. The number of monthly hospitalized children for ARIs did not return to the pre-lockdown number in the 20 months following the lockdown (Fig. 1). The median number of hospitalizations per month of children were 1784 before and reduced to 1,118 after the lockdown. There was a significant difference in the number of patients monthly between the two groups in pre- and post-lockdown ($t = 9.859, P < 0.0001$). To determine age specific differences in viral infections before and after the lockdown period, we divided the patients according to age into four groups, as follows (1) infants (newborn-1 year old), (2) toddlers (1–3 years old), (3) school children (3–6 years old), (4) school children (6–14 years old); the proportion of hospitalized children in each group before and after the lockdown is shown in Fig. 2A,B. There was a significant difference in age groups between pre- and post-lockdown ($P < 0.001$). There was no significant difference in sex ratio ($P = 0.8041$).
Figure 1. Number of detected cases by month (above) and the flowchart (below) of detection by DFA or GeXP-based PCR. Specimens were tested by DFA and *M. pneumoniae* PCR in pre-lockdown (orange bar), and tested by GeXP-based multiplex reverse transcription PCR assay (grey bar). DFA, Direct Immunofluorescence Assay; pre-lockdown, from July 2018 to January 2020, Lockdown, from February to May 2020, post-down, from June 2020 to January 2022.

Figure 2. The proportion of each group in pre- and post-lockdown. Pre-lockdown (A), from July 2018 to January 2020, post-down (B), from July 2020 to January 2022.
The prevalence of respiratory pathogens in the pre- and post-lockdown period. In total 30,559 specimens collected were tested by DFA and Mp PCR from July 2019 to January 2020 and 3350 specimens were tested by GeXP-based multiplex reverse transcription PCR assay from September 2019 to January 2020. All specimens collected during and after the lockdown (22,416) were tested by GeXP-based multiplex reverse transcription PCR assay as depicted in Fig. 1. The detection rates of Mp, RSV, AdV, HPIV, InfA and InfB before the lockdown were 16.9%, 6.3%, 2.7%, 1.8%, 1.3% and 0.2%, respectively. The most frequently detected pathogens after the lockdown were HRV (26.7%), RSV (18.2%), HPIV (8.6%), HMPV (5.1%), AdV (2.6%), Mp (1.4%), followed by HBoV (2.4%), HCOV (1.9%), InfB (1.5%), InfA (0.03%) and Cp (0.6%).

We determined the prevalence of the six major pathogens including Mp, InfA, InfB, AdV, RSV, and HPIV before and after the lockdown period. It was found that the detection rate of InfA and Mp decreased significantly during and after the lockdown, the detection rate of Mp decreased from 15 to 40% to about 1%, while infection rates with RSV and HPIV were consistent in the pre- and post-lockdown period (Fig. 3A–F). AdV showed a decrease during the lockdown, however the number of infections quickly increased after the lockdown.

The lock down measures clearly distorted the common seasonal dynamics of respiratory infections. In Southern China, InfA peaks every year in January and normally there is also a small peak in August21, these seasonal patterns completely disappeared. Mp has normally a high detection rate throughout the year, as was seen especially in 2019. RSV peaked in both summer and autumn in the pre-lockdown and post-lockdown period, however the peak in March during the post-lockdown period did not appear. HPIV prevalence showed the same trend pre- and post-and peaked in May and November. Also AdV in pre-lockdown and post-lockdown have the same trend, both are common in the winter and spring season. The transition between summer and autumn is the time with the lowest detection rates for this pathogen. InfB is normally sporadically detected, however the detection rate has increased from 0.3% in June 2021 to 4.0% in January 2022.

From September 2019, we have added HRV, HMPV, HBoV, HCOV and Cp to our PCR-based respiratory pathogen detection panel. This was used to determine the detection rate between September 2019 and January 2022. We found that the detection rate of HRV was above 10% throughout the year, with the highest detection rate in April and November each year. The detection rate of HMPV was lower throughout the year, but the highest detection rate was in January 2020 to 2022. HCOV has the highest detection rate in December 2020 to 2021, and HBoV is the highest in November and December: Cp is at a low level throughout the year, mainly detected in neonates and patients within 6 months, and in lockdown, Cp is the only pathogen with an increased detection rate (Fig. 3).

Comparison of PICU admission and respiratory pathogens detection rates between the pre- and post-lockdown period. A total of 1366 (4.03%) and 817 (3.85%) children were admitted to the PICU, before and after the lockdown, respectively. The rate of admission to the PICU decreased after the lockdown, however there was no significant difference found compared to the pre-lockdown period (p > 0.05). The detection rates of AdV, Mp and InfA in children admitted to the PICU were reduced from 4.4%, 3.7% and 2.5% pre-lockdown to 0.7%, 0.2% and 0.5% post-lockdown. In contrast, HPIV and RSV were increased from 0.7% and 8.9% to 3.7% and 11.6%. We found the detection rate of HBoV reached 4.2% in post-lockdown, which was an important virus detected in PICU patients.

Comparison of detection rates of respiratory pathogens by different ages and gender before and after the lockdown. Comparison of pre-lockdown and post-lockdown, the changes of detection rates of respiratory pathogens in each age group were relatively consistent, and only the detection rate of HRV in the infant group decreased significantly in post-lockdown. The detection rate of Mp increased with age. InfA, adenovirus and HMPV had the highest detection rate in the pre-school group and the lowest in the infant group. Rhinovirus, RSV, HPIV and Cp had the highest detection rate in the infant group. HBoV and HCoV had the highest detection rates in the toddler group (Fig. 4).

The detection rate of Mp in female patients in the pre-lockdown period was significantly higher than that of male patients (p < 0.001), but there was no difference post-lockdown (p = 0.6748), due to the significant decrease in the detection rate. In contrast, RSV was significantly more frequently detected in males than in females in post-lockdown (p = 0.0012), while no difference was observed before the lockdown (p = 0.0575).

Discussion

Shenzhen is located in southern China, after the first case of COVID-19 imported from Hubei province on January 19, 2020, the strictest control measures (lockdown) were implemented from February to May 2020. Under the prevention and control of the public health measures the number of hospitalized children with ARIs has dropped significantly20. Only 16.3% of the total hospitalized patients in February to May 2019 were children with acute respiratory infections. This is likely due to the strict prevention and control measures, the medical treatment of children with respiratory diseases in local social health centers to prevent travelling with diseased children, and the decline in the number of people returning to Shenzhen from outside the province.

We had chosen for the time span covering the two influenza seasons before the lockdown. The detection rate of InfA decreased significantly post-lockdown, only very few positive samples were detected in the post-lockdown period until January 2022, which is consistent with other studies5,6,16–18,20–23. Also other pathogens, such as Mp and AdV, which are predominant in older children, were also significantly reduced. Interestingly, it was found that the prevalence of RSV and HPIV increased after the lockdown. It may be due to a phenomenon called viral interference where one virus blocks the growth of another virus21,24. Although this is a limitation of the study, caused by the fact that inclusion was based on routine diagnostics and thus dependent on the implemented diagnostic methods, the increase is found for multiple but not all viruses.
Public health measures implemented during the COVID-19 pandemic strongly impacted the incidence of common respiratory pathogens\textsuperscript{1,3,16,25,26}. InfA almost disappeared. This may be related to the fact that people wear masks and maintain social distance. It might also be related to the fact that Shenzhen has carried out influenza target group vaccination before December 2020 in order to prevent the double epidemic of influenza.

\textbf{Figure 3.} The seasonal prevalence of 11 respiratory pathogens (A–F). \textit{Mycoplasma pneumoniae} (Mp), HRV, RSV, HMPV, influenza A, HCOV, influenza B, HBoV, HPIV and AdV the percentage detected was plotted as a function of time (indicated in months) before, during or after lockdown. Black line represented Mp, RSV, InfA, InfB, HPIV and AdV in (A–F) from July 2018 to January 2022, red line was HRV, HMPV, HCOV, HBoV, \textit{Cp} in A-E from September 2019 to January 2022. AdV, adenovirus; HRV, human rhinovirus; HPIV, human parainfluenza viruses 1–4; RSV, respiratory syncytial virus; HMPV, human metapneumovirus; HCOV, human coronavirus; InfA/B, influenza A/influenza B; HBoV, human bocavirus; \textit{Cp}, \textit{Chlamydia pneumoniae}.
and SARS-CoV-2. The detection rate of **Mp** decreased from 10 to 40% to about 1%, which may be related to the annual change of its prevalence as a consequence of the public health measures. RSV did not appear after the peak detection rate in March, and the peak in summer and autumn in the first year after the pandemic of COVID-19 was delayed by about a month compared to the second year. However, it may also be related to the subtype of the epidemic strain, as well as to the climatic conditions in different years.

Severe respiratory tract infection is an important cause of death in children, and it is of great significance to explore respiratory pathogens in children admitted to the PICU. In this study, under the general public health measures in the post-lockdown period, the proportion of children admitted to the PICU was the same as before the lockdown. However, we also found that the detection rate of respiratory pathogens in the PICU was consistent with the overall epidemiological detection rate in the study period. It should be pointed out that in post-lockdown, we used PCR detection to increase the detection of various viruses, and found that the detection rate of **HBoV** in children admitted to PICU reached 4.2%, which is a very important pathogen. However, more research is needed to understand the role of **HBoV** in children with severe respiratory infections.
Data availability
The key information and data generated and/or analyzed during this study were included in this article.

Received: 26 June 2022; Accepted: 27 September 2022
Published online: 08 October 2022

References
1. Haddadin, Z. et al. Acute respiratory illnesses in children in the SARS-CoV-2 pandemic: Prospective multicenter study. Pediatrics 148(2), e2021051462 (2021).

2. Lai, S. et al. Effect of non-pharmaceutical interventions to contain COVID-19 in China. Nature 585(7825), 410–413 (2020).

3. Baker, R. E. et al. The impact of COVID-19 nonpharmaceutical interventions on the future dynamics of endemic infections. Proc. Natl. Acad. Sci. USA 117(48), 30547–30553 (2020).

4. Zhao, Z. et al. Stringent nonpharmaceutical interventions are crucial for curbing COVID-19 transmission in the course of vaccination: A case study of South and Southeast Asian countries. Healthc. (Basel) 9(10), 1292 (2021).

5. Grote, U. et al. Measures to cope with the COVID-19 pandemic in Germany: Nonpharmaceutical and pharmaceutical interventions. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 64(4), 435–445 (2021).

6. León, T. M. et al. Nonpharmaceutical interventions remain essential to reducing coronavirus disease 2019 burden even in a well-vaccinated society: A modeling study. Open Forum Infect. Dis. 8(9), ofab415 (2021).

7. Huh, K. et al. Impact of nonpharmaceutical interventions on the incidence of respiratory infections during the coronavirus disease 2019 (COVID-19) outbreak in Korea: A nationwide surveillance study. Clin. Infect. Dis. 72(7), e184–e191 (2021).

8. Aledort, J. E., Lurie, N., Wasserman, J. & Bozzette, S. A. Non-pharmaceutical public health interventions for pandemic influenza: An evaluation of the evidence base. BMC Public Health 7, 208 (2007).

9. Chiu, S. S. et al. Effects of nonpharmaceutical COVID-19 interventions on pediatric hospitalizations for other respiratory virus infections, Hong Kong. Emerg. Infect. Dis. 28(1), 62–68 (2022).

10. Geng, Y., Li, G. & Zhang, L. The impact of COVID-19 interventions on influenza and mycobacterium tuberculosis infection. Front. Public Health 9, 672568 (2021).

11. Li, L. et al. Comparison of 11 respiratory pathogens among hospitalized children before and during the COVID-19 epidemic in Shenzhen, China. Virol. J. 18(1), 202 (2021).

12. Xiao, J. et al. Co-benefits of nonpharmaceutical intervention against COVID-19 on infectious diseases in China: A large population-based observational study. Lancet Reg. Health West Pac. 17, 100282 (2021).

13. Huang, Q. S. et al. Impact of the COVID-19 nonpharmaceutical interventions on influenza and other respiratory viral infections in New Zealand. Nat. Commun. 12(1), 1001 (2021).

14. Fukuda, Y. et al. Surveillance in hospitalized children with infectious diseases in Japan: Pre- and post-coronavirus disease 2019 (COVID-19) outbreak in Japan: A nationwide surveillance study. Clin. Infect. Dis. 72(7), e184–e191 (2021).

15. Ullrich, A. et al. Impact of the COVID-19 pandemic and associated non-pharmaceutical interventions on other notifiable infectious diseases in Germany: An analysis of national surveillance data during week 1–2016—week 32–2020. Lancet Reg. Health Eur. 6, 100103 (2021).

16. Boéllé, P. Y. et al. Excess cases of influenza-like illnesses synchronous with coronavirus disease (COVID-19) epidemic, France, March 2020. Euro Surveill. 25(14), 2000326 (2020).

17. Sakamoto, H., Ishikane, M. & Ueda, P. Seasonal influenza activity during the SARS-CoV-2 outbreak in Japan. JAMA 323(19), 1639–1647 (2021).

18. Ullrich, A. et al. Impact of the COVID-19 pandemic and associated non-pharmaceutical interventions on other notifiable infectious diseases in Germany: An analysis of national surveillance data during week 1–2016—week 32–2020. Lancet Reg. Health Eur. 6, 100103 (2021).

19. Boéllé, P. Y. et al. Excess cases of influenza-like illnesses synchronous with coronavirus disease (COVID-19) epidemic, France, March 2020. Euro Surveill. 25(14), 2000326 (2020).

17. Sakamoto, H., Ishikane, M. & Ueda, P. Seasonal influenza activity during the SARS-CoV-2 outbreak in Japan. JAMA 323(19), 1639–1647 (2021).

18. Soo, R. et al. Decreased influenza incidence under COVID-19 control measures, Singapore. Emerg. Infect. Dis. 26(8), 1933–1935 (2020).

19. Murillo-Zamora, E. et al. Physical distancing reduced the incidence of influenza and supports a favorable impact on SARS-CoV-2 spread in Mexico. J. Infect. Dev. Cities. 14(9), 953–956 (2020).
20. Cheng, W. et al. Successful interruption of seasonal influenza transmission under the COVID-19 rapid response in Zhejiang Province, China. Public Health 189, 123–125 (2020).
21. Cowling, B. J. et al. Impact assessment of non-pharmaceutical interventions against coronavirus disease 2019 and influenza in Hong Kong: An observational study. Lancet Public Health 5(5), e279–e288 (2020).
22. Tempia, S. et al. Decline of influenza and respiratory syncytial virus detection in facility-based surveillance during the COVID-19 pandemic, South Africa, January to October 2020. Euro Surveill. 26(29), (2021).
23. Feng, L. et al. Impact of COVID-19 outbreaks and interventions on influenza in China and the United States. Nat. Commun. 12(1), 3249 (2021).
24. Latorre-Margalef, N. et al. Competition between influenza A virus subtypes through heterosubtypic immunity modulates re-infection and antibody dynamics in the mallard duck. PLoS Pathog. 13(6), e1006419 (2017).
25. Lei, H. et al. Nonpharmaceutical interventions used to control COVID-19 reduced seasonal influenza transmission in China. J. Infect. Dis. 222(11), 1780–1783 (2020).
26. Lagacé-Wiens, P. et al. Impact of nonpharmaceutical interventions on laboratory detections of influenza A and B in Canada. Can. Commun. Dis. Rep. 47(3), 142–148 (2021).

Acknowledgements
Not applicable.

Author contributions
H.W. and W.W. designed this study; L.L. and R.W. collected data; L.M.V., H.W. and M.I.J. performed the statistical analyses and outcome assessments, and wrote the paper. Y.Z., Z.X., Y.C. and W.W. also contributed to the statistical analyses and the outcome assessments. All authors read and approved the final manuscript.

Funding
We appreciate the encouragement from our funders that made this project possible. This work was supported by Shenzhen Fund for Guangdong Provincial High-level Clinical Key Specialties [SZGSP012], Shenzhen Key Medical Discipline Construction Fund [SZXK032] Guangdong Provincial High-level Hospital Construction Special Fund (YNKT2021-ZZ10) and Shenzhen Fundamental Research Program [JCYJ20190809170007587].

Competing interests
The authors declare no competing interests.

Additional information
Correspondence and requests for materials should be addressed to W.W.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022